As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Protein–protein interactions (PPI) were once considered 'undruggable', but clinical
successes, driven by advanced methods in drug discovery, have challenged that notion …

Octahedral Ir (III) complexes bearing cyclometalated ligands exhibit a great stability in
biological media and are excellent therapeutical and phototherapeutical candidates for …

Bromodomain and extraterminal (BET) proteins bind acetylated lysine residues in histones
and nonhistone proteins via tandem bromodomains and regulate chromatin dynamics …

Functional components extracted from algal biomass are widely used as dietary and health
supplements with a variety of applications in food science and technology. In contrast, the …

Clinical development of bromodomain and extra‐terminal (BET) protein inhibitors differs
from the traditional course of drug development. These drugs are simultaneously being …

Phosphorescent transition metal complexes have been intensively investigated, since these
luminophores are distinctively different from fluorescent chromophores in terms of the nature …

To develop the next-generation Pt drug with remarkable activity and low toxicity to maximally
inhibit tumor growth, we optimized a Pt (II) thiosemicarbazone compound (C4) with …

Bromodomain-containing protein 4 (Brd4) plays an important role in mediating the
expression of genes involved in cancers and non-cancer diseases such as inflammatory …

Abstract Cyclin-dependent kinase 9 (CDK9) activity is correlated with worse outcomes of
triple-negative breast cancer (TNBC) patients. The heterodimer between CDK9 with cyclin …